SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) – CFHI
SARS-Related Coronavirus 2 Lineage B.1.617.2; Kappa Variant (Isolate: USA/CA-Stanford-15_S02/2021) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/CAStanford-15_S02/2021 (also referred to as hCoV-19/USA/CA-SU-15_S02/2021) was isolated from a midturbinate nasal swab from a 29-year old male in California, USA on March 5, 2021. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/CA Stanford-15_S02/2021 is assigned lineage B.1.617.1 and GISAID clade G using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. SARS-CoV-2, lineage B.1.617.1 was first detected in India and labelled as a variant of interest (VOI). It was labelled as Kappa variant by the World Health Organization (WHO). The complete genome of SARS-CoV-2, isolate hCoV-19/USA/CAStanford-15_S02/2021 has been sequenced (GISAID: EPI_ISL_1675223). Each frozen aliquot contains 1 mL of heat inactivated viral culture fluid. The culture fluid was clarified prior to heat inactivation by centrifugation to remove cellular debris. The pre-inactivation titer was determined from an infectious aliquot. Viral inactivation is verified after heat inactivation by the absence of viral growth in tissue culture-based infectivity assays.
Heat inactivated viral culture fluids are sold as consumable testing materials. The suitability and performance characteristics should be determined by your laboratory for each intended usage. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.
For BSL-2 or BSL-3 compliant labs only. CCL required / -20° C.